Related Experiment Video
Updated: Feb 14, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Avelumab: a new standard for treating metastatic Merkel cell carcinoma
Mairead Baker1,2, Lisa Cordes2,3, Isaac Brownell1,2
1a Dermatology Branch , National Institute of Arthritis and Musculoskeletal and Skin Disorders , Bethesda , MD , USA.
Introduction:
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer. Although MCC is chemosensitive, responses to traditional chemotherapeutic agents are not durable. Avelumab, a novel anti-PD-L1 immune checkpoint inhibitor, recently became the first FDA-approved agent for the treatment of metastatic MCC and represents a new option to improve patient survival. Areas covered: This article presents an overview of MCC and summarizes the development of avelumab in the treatment of metastatic MCC. Preclinical studies, phase 1 and phase 2 clinical trials, and the safety profile of avelumab are reviewed. Future perspectives and ongoing studies are also discussed. Expert commentary: Avelumab demonstrated rapid and durable responses and a manageable safety profile in the treatment of metastatic MCC. Patient outcomes are favorable when compared to historical responses to standard chemotherapy. Ongoing clinical trials will continue to characterize avelumab and its optimal use in MCC therapy.
Insights
Avelumab, an anti-PD-L1 therapy, offers durable responses for metastatic Merkel cell carcinoma (MCC), a rare skin cancer. This immunotherapy represents a significant advancement over traditional chemotherapy for improving patient survival.
Area of Science:
- Oncology
- Immunotherapy
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer.
- Traditional chemotherapy offers limited durable responses in metastatic MCC.
- Avelumab is a novel anti-PD-L1 immune checkpoint inhibitor.
Purpose of the Study:
- To provide an overview of Merkel cell carcinoma.
- To summarize the development and efficacy of avelumab for metastatic MCC.
- To review preclinical and clinical trial data, including safety and future perspectives.
Main Methods:
- Review of preclinical studies.
- Analysis of Phase 1 and Phase 2 clinical trials.
- Evaluation of avelumab's safety profile in MCC patients.
Main Results:
- Avelumab demonstrated rapid and durable responses in metastatic MCC.
- The safety profile of avelumab was manageable.
- Patient outcomes showed favorable comparison to historical chemotherapy responses.
Conclusions:
- Avelumab is the first FDA-approved agent for metastatic MCC, offering a new treatment option.
- The immunotherapy shows promise for improving patient survival in advanced MCC.
- Ongoing trials aim to further define avelumab's role and optimal use in MCC therapy.
Related Concept Videos
Standard Electrode Potentials
Standard Enthalpy of Formation
Measurement: Standard Units
Calculating Standard Free Energy Changes
Standard Solutions
Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...

